Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus.

Eledrisi, Mohsen; Suleiman, Noor Nabeel; Salameh, Obada; Khair Hamad, Mohammad; Rabadi, Omar; Mohamed, Ahmed; Al Adawi, Rana; Salam, Abdul

Abstract

Insulin glargine is recombinant human insulin analog that is commonly used in patients with type 2 diabetes as well as those with type 1 diabetes. Pharmacokinetic and pharmacodynamics studies of insulin glargine had shown that it has an onset of action that ranged from 1.2 to 1.8 h while its duration of action is 18 to 26 h. Because of its long duration of action insulin glargine is usually prescribed once daily. However, several reports have shown that the administration of insulin glargine once daily is not enough to achieve adequate glucose control in some patients requiring a twice daily dosing. The first report on using insulin glargine twice daily was published shortly after its availability. It described a patient with type 1 diabetes who had consistently elevated bedtime glucose values on once daily insulin glargine administered in the evening. There was significant improvement in glucose values after changing the frequency of insulin glargine to twice daily as a split dose every 12 h. Albright and colleagues found that twice daily glargine therapy was required in patients with type 1 diabetes who developed morning hypoglycemia and/or afternoon hyperglycemia while on once daily therapy; the twice daily regimen was associated with a significant reduction in HbA1c levels compared to patients who were on once daily therapy.

Citation

ELEDRISI, M., SULEIMAN, N.N., SALAMEH, O., HAMAD, M.K., RABADI, O., MOHAMED, A., AL ADAWI, R. and SALAM, A. 2019. Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. Journal of clinical and translational endocrinology [online], 15, pages 35-36. Available from: https://doi.org/10.1016/j.jcte.2018.12.002

• Journal Article Type: Article
• Acceptance Date: Dec 6, 2018
• Online Publication Date: Dec 11, 2018
• Publication Date: Mar 31, 2019
• Deposit Date: Jun 11, 2021
• Publicly Available Date: Jun 11, 2021
• Journal: Journal of clinical and translational endocrinology
• Print ISSN: 2214-6237
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 15
• Pages: 35-36
• DOI: https://doi.org/10.1016/j.jcte.2018.12.002
• Keywords: Insulin glargine; Type 2 diabetes; Uncontrolled glucose
• Public URL: https://rgu-repository.worktribe.com/output/1352332